These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 33070553

  • 1. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L, Cai J, Tan Z, Meng X, Li R, Li Y, Jiang C.
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
    Yamashita AS, da Costa Rosa M, Borodovsky A, Festuccia WT, Chan T, Riggins GJ.
    Neuro Oncol; 2019 Feb 14; 21(2):189-200. PubMed ID: 30184215
    [Abstract] [Full Text] [Related]

  • 4. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
    Li K, Ouyang L, He M, Luo M, Cai W, Tu Y, Pi R, Liu A.
    Oncotarget; 2017 Apr 25; 8(17):28865-28879. PubMed ID: 28427200
    [Abstract] [Full Text] [Related]

  • 5. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
    Wang JB, Dong DF, Wang MD, Gao K.
    Asian Pac J Cancer Prev; 2014 Apr 25; 15(1):427-32. PubMed ID: 24528069
    [Abstract] [Full Text] [Related]

  • 6. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
    Subramani E, Radoul M, Najac C, Batsios G, Molloy AR, Hong D, Gillespie AM, Santos RD, Viswanath P, Costello JF, Pieper RO, Ronen SM.
    Cancer Res; 2020 Nov 15; 80(22):5098-5108. PubMed ID: 32958546
    [Abstract] [Full Text] [Related]

  • 7. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, Haase S, Koschmann C, Calinescu AA, Kamran N, Saxena M, Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA, Tagett R, Venneti S, Brosnan-Cashman J, Meeker A, Gorbunova V, Zhao L, Kremer DM, Zhang L, Lyssiotis CA, Jones L, Herting CJ, Ross JL, Hambardzumyan D, Hervey-Jumper S, Figueroa ME, Lowenstein PR, Castro MG.
    Sci Transl Med; 2019 Feb 13; 11(479):. PubMed ID: 30760578
    [Abstract] [Full Text] [Related]

  • 8. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
    Han B, Cai J, Gao W, Meng X, Gao F, Wu P, Duan C, Wang R, Dinislam M, Lin L, Kang C, Jiang C.
    Cancer Lett; 2018 Apr 10; 419():280-290. PubMed ID: 29378238
    [Abstract] [Full Text] [Related]

  • 9. Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.
    Saville KM, Al-Rahahleh RQ, Siddiqui AH, Andrews ME, Roos WP, Koczor CA, Andrews JF, Hayat F, Migaud ME, Sobol RW.
    DNA Repair (Amst); 2024 Aug 10; 140():103700. PubMed ID: 38897003
    [Abstract] [Full Text] [Related]

  • 10. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
    Lu Y, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su YT, Bautista W, Moon SI, MacDonald J, Ewend MG, Gilbert MR, Yang C, Wu J.
    Cancer Res; 2017 Apr 01; 77(7):1709-1718. PubMed ID: 28202508
    [Abstract] [Full Text] [Related]

  • 11. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B, Meng X, Wu P, Li Z, Li S, Zhang Y, Zha C, Ye Q, Jiang C, Cai J, Jiang T.
    Theranostics; 2020 Apr 01; 10(7):3351-3365. PubMed ID: 32194873
    [Abstract] [Full Text] [Related]

  • 12. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH, Yang L, Chen JX, Li QR, Zhu LR, Xu QF, Huang GH, Zhang ZX, Xiang Y, Du L, Zhou Z, Lv SQ.
    Cancer Commun (Lond); 2019 Dec 03; 39(1):81. PubMed ID: 31796105
    [Abstract] [Full Text] [Related]

  • 13. PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
    Koncar RF, Chu Z, Romick-Rosendale LE, Wells SI, Chan TA, Qi X, Bahassi EM.
    Oncotarget; 2017 Feb 28; 8(9):15827-15837. PubMed ID: 28178660
    [Abstract] [Full Text] [Related]

  • 14. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
    Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A.
    Tumour Biol; 2014 Jun 28; 35(6):5911-20. PubMed ID: 24590270
    [Abstract] [Full Text] [Related]

  • 15. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
    Li C, Feng S, Chen L.
    Mol Cell Biochem; 2021 Feb 28; 476(2):699-713. PubMed ID: 33106913
    [Abstract] [Full Text] [Related]

  • 16. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
    Shi J, Sun B, Shi W, Zuo H, Cui D, Ni L, Chen J.
    Tumour Biol; 2015 Feb 28; 36(2):655-62. PubMed ID: 25283382
    [Abstract] [Full Text] [Related]

  • 17. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS, Peng S, Dancy JG, Galisteo R, Eschbacher JM, Castellani RJ, Heath JE, Legesse T, Kim AJ, Woodworth GF, Tran NL, Winkles JA.
    J Neurooncol; 2018 Jun 28; 138(2):241-250. PubMed ID: 29453678
    [Abstract] [Full Text] [Related]

  • 18. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG, Ronen SM.
    Neuroimage Clin; 2016 Jun 28; 12():180-9. PubMed ID: 27437179
    [Abstract] [Full Text] [Related]

  • 19. Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
    Li H, Liu Q, Chen Z, Wu M, Zhang C, Su J, Li Y, Zhang C.
    Cell Death Dis; 2021 Mar 05; 12(3):252. PubMed ID: 33674567
    [Abstract] [Full Text] [Related]

  • 20. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
    Ding C, Yi X, Chen X, Wu Z, You H, Chen X, Zhang G, Sun Y, Bu X, Wu X, Lin Z, Gu J, Lin Y, Kang D.
    J Exp Clin Cancer Res; 2021 May 11; 40(1):164. PubMed ID: 33975615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.